5. Conclusions
RA, overweight, weight loss, PCOS
OBESE
In our study, for an identical degree of weight loss, dulaglutide combined with a CRD regimen did not produce a more pronounced reduction in visceral fat than the CRD regimen. Dulaglutide combined with CRD could favor high efficiency in achieving targeted weight loss and provide additional benefits in terms of the HbA1c and PPG levels as compared with the CRD regimen alone. The interventions both had similar positive effects in improving menstrual frequency and reducing levels of blood pressure, insulin, aminotransferases, lipids, total fat mass, total lean mass, and abdominal SAT mass after equivalent weight loss. These findings support the importance of dietary intervention as a first-line treatment in women with PCOS, and GLP-1 RA therapy offers an effective and generally tolerable adjunct therapy to aid in achieving weight targets based on dietary therapy in overweight and obese women with PCOS.